The Evolving Landscape in Biosimilars

Description: The outlook for biosimilars has changed dramatically over the last five years, due to product development progress, regulatory guidance, and new company strategies. Biosimilars have now moved well past proof of concept, but due to the levels of competition anticipated, only the most suitable will be profitable in the long run. This report analyzes the current biosimilars market, how it's evolved and how it will continue to develop.

Features and Benefits:
- Determine which strategies will drive success in the evolving biosimilars landscape
- Understand the factors that could impact the long-term outlook for biosimilars

Key Questions Answered:
- How competitive will the biosimilars market be?
- What do industry participants feel are the greatest challenges?
- Which are the next big reference products to go after?

Contents:
1. Executive Summary
   - Analysis headlines and metrics
   - Notes and caveats

2. Past Developments
   - What has changed over 2009-14?
   - Bibliography

3. Company Strategies
   - Greater competition in biosimilars expected following major new entrants
   - Strengthening through deals
   - Bibliography

4. Pipeline Progress
   - Major market Phase III trials triggered by EU pathway implementation
   - Second wave and into the US
   - Sandoz is the leading player in terms of product development
   - Bibliography

5. Profitability and Challenges
   - Investment by new entrants means lower returns for all
   - Litigation will impact time to market in many cases
   - Interchangeability remains an unknown
   - Bibliography

6. Next Target Opportunities
   - Biosimilars are dependent upon expiring reference brands
   - Insight from the overall development status of biosimilars
   - Next-wave target reference products
   - Bibliography

7. Longer-Term Outlook and Considerations
   - Near-term drivers and resistors of biosimilars
   - Longer-term factors
   - Bibliography

List of Figures:
Figure 1: Key summary facts and figures
Figure 2: Biosimilars survey: views on the overall outlook
Figure 3: Biosimilars survey: views on expected level of biosimilar usage in 2020 compared to views five years ago, by respondents
Figure 4: Biosimilars survey: views on the number of companies in the biosimilars space in 2014
Figure 5: The shift towards major pharmaceutical companies in biosimilars
Figure 6: Global deals in biosimilars, 1999-2014
Figure 7: Mentions of biosimilars in annual reports across selected major pharmaceutical companies, 2003-13
Figure 8: Mentions of biosimilars in annual reports - Teva, 2003-13
Figure 9: Mentions of biosimilars in annual reports - Merck & Co, 2003-13
Figure 10: Mentions of biosimilars in annual reports - Pfizer, 2003-13
Figure 11: Mentions of biosimilars in annual reports - Biogen Idec, 2003-13
Figure 12: Mentions of biosimilars in annual reports - Amgen, 2003-13
Figure 13: Mentions of biosimilars in annual reports - Boehringer Ingelheim, 2003-13
Figure 14: Major market Phase III clinical trials of biosimilars to 2010
Figure 15: Cumulative major market Phase III clinical trials of biosimilars, by molecule type, 2000-15
Figure 16: US/EU Phase III biosimilar trial count and FDA biosimilar program metrics
Figure 17: Major market Phase III clinical trials of biosimilars, by reference product, 2001-19
Figure 18: US/EU Phase III clinical trials of biosimilars, by company and status
Figure 19: Biosimilars survey: more competition in major markets
Figure 20: Price discounts for generics (actual) and biosimilars (estimated)
Figure 21: Global adalimumab biosimilars pipeline, by stage and region
Figure 22: The role of patent protection and challenges in determining biosimilar launch timing
Figure 23: The impact on biosimilar opportunity of market share loss to next-generation innovator products
Figure 24: Biosimilars survey: reduced expectation for implementation of automatic substitution
Figure 25: Expiry dates of US biologic molecule exclusivity periods, 1998-2026
Figure 26: Biosimilar development versus reference product peak sales - example guide to the charts
Figure 27: Comparison of biosimilar development status in major markets versus rest of world/global markets
Figure 28: Companies with biosimilars in any stage of major market development versus clinical stages only
Figure 29: Biosimilar opportunities timeline, 1998-2026
Figure 30: Biosimilars survey: threats and drivers

List of Tables:
Table 1: Analysis headlines
Table 2: Standout events in the biosimilars landscape, 2008-14
Table 3: Key major biosimilar market deals, 2008-14
Table 4: Longer-term drivers and resistors of biosimilars

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3445979/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>The Evolving Landscape in Biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3445979/">http://www.researchandmarkets.com/reports/3445979/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCBR8FV4</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 11250</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp